MYBL2 and central nervous system cancer: MYBL2 induction by AKT/FOXM1 signaling was associated with glioma progression and anti-apoptotic mechanisms; however, the AKT inhibitor MK-2206 strongly suppressed MYBL2 in U251 glioma cells and can be a useful drug to tackle the anti-apoptotic mechanisms in glioma based on the AKT-FOXM-MYBL2 axis[169].